Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Accounts Payable: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHUKRAPHAR Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
61 GF Score
Price ₹41.55
GF Value ₹8.56
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Accounts Payable?

Shukra Pharmaceuticals NSE:SHUKRAPHAR +0.27% 61 Accounts Payable is ₹0.0 Mil as of Jun. 2026. GuruFocus rates NSE:SHUKRAPHAR with a GF Score™ of 61/100 and a GF Value™ of ₹8.56 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Shukra Pharmaceuticals's Accounts Payable for the quarter that ended in Jun. 2026 was ₹0.0 Mil.

Shukra Pharmaceuticals's quarterly Accounts Payable increased from Dec. 2025 (₹0.0 Mil) to Mar. 2026 (₹100.7 Mil) but then declined from Mar. 2026 (₹100.7 Mil) to Jun. 2026 (₹0.0 Mil).

Shukra Pharmaceuticals's annual Accounts Payable increased from Mar. 2024 (₹72.2 Mil) to Mar. 2025 (₹92.2 Mil) and increased from Mar. 2025 (₹92.2 Mil) to Mar. 2026 (₹100.7 Mil).

Shukra Pharmaceuticals Accounts Payable Related Terms

Shukra Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Shukra Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shukra Pharmaceuticals Accounts Payable Chart

Shukra Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.90 336.22 72.21 92.16 100.65

Shukra Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 82.75 0.00 100.65 0.00
NSE:SHUKRAPHAR
61GF Score
Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹0.0 Mil mean?
Shukra Pharmaceuticals (NSE:SHUKRAPHAR) has a Accounts Payable of ₹0.0 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' Accounts Payable too high?
Shukra Pharmaceuticals' current Accounts Payable is ₹0.0 Mil. Overall, Shukra Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Accounts Payable compare to ?
Shukra Pharmaceuticals' Accounts Payable of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current Accounts Payable is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (NSE:SHUKRAPHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.56, compared to a current price of ₹41.55 — trading 385.4% above its estimated fair value. The current Accounts Payable is ₹0.0 Mil. Shukra Pharmaceuticals' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Shukra Pharmaceuticals (NSE:SHUKRAPHAR), the current Accounts Payable is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹41.55 is trading 385.4% above its estimated GF Value™ of ₹8.56. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:SHUKRAPHAR:

  • Accounts Payable: ₹0.0 Mil
  • GF Value™: ₹8.56 vs. price of ₹41.55 (385.4% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NSE:SHUKRAPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Comparable Companies
Other Exchanges 524632:India
Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
61GF Score

Get the complete analysis for NSE:SHUKRAPHAR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹41.55
Price
₹8.56
GF Value